Trials / Not Yet Recruiting
Not Yet RecruitingNCT07143864
Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis
Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis: A Randomized, Double-blind, Placebo-controlled Study
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- First Affiliated Hospital of Chongqing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Stapokibart | A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha |
| OTHER | Placebo drug | Placebo drugs without Stapokibart |
Timeline
- Start date
- 2025-09-15
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2025-08-27
- Last updated
- 2025-08-27
Source: ClinicalTrials.gov record NCT07143864. Inclusion in this directory is not an endorsement.